Comparing Immuron (NASDAQ:IMRN) & Applied Therapeutics (NASDAQ:APLT)

Immuron (NASDAQ:IMRN) and Applied Therapeutics (NASDAQ:APLT) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, dividends, risk, institutional ownership, valuation, profitability and analyst recommendations.

Analyst Recommendations

This is a summary of current ratings for Immuron and Applied Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immuron	1	0	0	0	1.00
Applied Therapeutics	1	2	0	0	1.67

Applied Therapeutics has a consensus target price of $1.00, suggesting a potential upside of 870.87%. Given Applied Therapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe Applied Therapeutics is more favorable than Immuron.

Profitability

This table compares Immuron and Applied Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Immuron	N/A	N/A	N/A
Applied Therapeutics	N/A	-340.84%	-175.00%

Insider and Institutional Ownership

0.1% of Immuron shares are held by institutional investors. Comparatively, 98.3% of Applied Therapeutics shares are held by institutional investors. 7.0% of Immuron shares are held by company insiders. Comparatively, 1.6% of Applied Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Immuron and Applied Therapeutics”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immuron	$4.72 million	1.91	-$3.38 million	N/A	N/A
Applied Therapeutics	$1.00 million	15.86	-$105.62 million	($0.10)	-1.03

Immuron has higher revenue and earnings than Applied Therapeutics.

Risk & Volatility

Immuron has a beta of 1.15, suggesting that its stock price is 15% more volatile than the S&P 500. Comparatively, Applied Therapeutics has a beta of 2.08, suggesting that its stock price is 108% more volatile than the S&P 500.

About Immuron

Immuron Limited, a biopharmaceutical company, researches and develops oral immunotherapy polyclonal antibodies for the treatment and prevention of infectious and immune modulated diseases in Australia, the United States, and internationally. The company operates through two segments, Research and Development, and Hyperimmune Products. The company markets Travelan and Protectyn for the prevention of travellers' diarrhea. Its lead product candidates include IMM-124E that is in Phase II clinical trials for non-alcoholic steatohepatitis, severe alcoholic hepatitis, and non-alcoholic fatty liver disease, as well as used in antiviral activity against the COVID-19 virus in laboratory studies; and IMM-529, a clinical stage product for clostridium difficile infections. Immuron Limited was founded in 1994 and is based in Carlton, Australia.

About Applied Therapeutics

Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG. It also develops AT-001 (also called caficrestat) that is in phase 3 clinical trials to treat diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy; and AT-003, which is in preclinical studies for the treatment diabetic retinopathy. The company has exclusive license and supply agreement with Mercury Pharma Group Limited to commercialize drug products containing AT-007. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.